Outsourcing-pharma2h
Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Outsourcing-pharma1d
Orbis Medicines bags €90 million Series A to develop oral competitors of biologics
Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...